UNLABELLED: Sclerostin is expressed by osteocytes and inhibits bone formation by osteoblasts. In this study, serum sclerostin was positively correlated with either lumbar spinal bone mineral density or T-score. Furthermore, serum sclerostin was increased after 6 months treatment with risedronate, whereas remained unchanged after 6 months teriparatide treatment. INTRODUCTION: The primary aim of this study was the evaluation of serum sclerostin levels in postmenopausal women and their association with bone mineral density (BMD) and bone turnover markers. The secondary aim was the evaluation of treatment with either teriparatide (TPTD) or risedronate (RIS) on serum sclerostin levels in women with postmenopausal osteoporosis. METHODS:Women with postmenopausal osteoporosis, assigned to receive either TPTD (TPTD group, n = 13) or RIS (RIS group, n = 36) for 6 months, and non-osteoporotic early postmenopausal women (NOEP group, n = 13) were recruited. Main outcome measure was serum sclerostin levels. RESULTS:Serum sclerostin was higher in the NOEP group at baseline compared with either TPTD group (p = 0.007) or RIS group (p = 0.049). Sclerostin was positively correlated with both lumbar spinal (LS) BMD (r = 0.353; p = 0.005) and T-score (r = 0.501; p < 0.001) and negatively correlated with intact parathyroid hormone (r = -0.343; p = 0.024) at baseline. Multiple regression analysis showed that either LS BMD (Beta = 0.653; p = 0.018) or T-score (Beta = 0.711; p = 0.005) were independent predictors of serum sclerostin levels. No significant correlation was observed between serum sclerostin and bone turnover markers or estradiol at baseline. Sclerostin was significantly increased 6 months post-treatment in RIS group (p = 0.002), whereas remained statistically unaffected in the TPTD group. CONCLUSIONS:Serum sclerostin is decreased in women with postmenopausal osteoporosis compared with non-osteoporotic early postmenopausal women and is positively correlated to either LS BMD or LS T-score. Furthermore, serum sclerostin was increased after 6 months treatment with RIS, whereas remained essentially unchanged after 6 months TPTD treatment.
RCT Entities:
UNLABELLED: Sclerostin is expressed by osteocytes and inhibits bone formation by osteoblasts. In this study, serum sclerostin was positively correlated with either lumbar spinal bone mineral density or T-score. Furthermore, serum sclerostin was increased after 6 months treatment with risedronate, whereas remained unchanged after 6 months teriparatide treatment. INTRODUCTION: The primary aim of this study was the evaluation of serum sclerostin levels in postmenopausal women and their association with bone mineral density (BMD) and bone turnover markers. The secondary aim was the evaluation of treatment with either teriparatide (TPTD) or risedronate (RIS) on serum sclerostin levels in women with postmenopausal osteoporosis. METHODS:Women with postmenopausal osteoporosis, assigned to receive either TPTD (TPTD group, n = 13) or RIS (RIS group, n = 36) for 6 months, and non-osteoporotic early postmenopausal women (NOEP group, n = 13) were recruited. Main outcome measure was serum sclerostin levels. RESULTS: Serum sclerostin was higher in the NOEP group at baseline compared with either TPTD group (p = 0.007) or RIS group (p = 0.049). Sclerostin was positively correlated with both lumbar spinal (LS) BMD (r = 0.353; p = 0.005) and T-score (r = 0.501; p < 0.001) and negatively correlated with intact parathyroid hormone (r = -0.343; p = 0.024) at baseline. Multiple regression analysis showed that either LS BMD (Beta = 0.653; p = 0.018) or T-score (Beta = 0.711; p = 0.005) were independent predictors of serum sclerostin levels. No significant correlation was observed between serum sclerostin and bone turnover markers or estradiol at baseline. Sclerostin was significantly increased 6 months post-treatment in RIS group (p = 0.002), whereas remained statistically unaffected in the TPTD group. CONCLUSIONS: Serum sclerostin is decreased in women with postmenopausal osteoporosis compared with non-osteoporotic early postmenopausal women and is positively correlated to either LS BMD or LS T-score. Furthermore, serum sclerostin was increased after 6 months treatment with RIS, whereas remained essentially unchanged after 6 months TPTD treatment.
Authors: L Joseph Melton; Anne C Looker; John A Shepherd; Michael K O'Connor; Sara J Achenbach; B Lawrence Riggs; Sundeep Khosla Journal: Osteoporos Int Date: 2005-04-06 Impact factor: 4.507
Authors: XiaoYan Tian; Rebecca B Setterberg; Xiaodong Li; Chris Paszty; Hua Zhu Ke; Webster S S Jee Journal: Bone Date: 2010-06-01 Impact factor: 4.398
Authors: A D Anastasilakis; D G Goulis; S A Polyzos; S Gerou; G N Koukoulis; Z Efstathiadou; M Kita; A Avramidis Journal: Int J Clin Pract Date: 2008-04-17 Impact factor: 2.503
Authors: Bingyu Mao; Wei Wu; Gary Davidson; Joachim Marhold; Mingfa Li; Bernard M Mechler; Hajo Delius; Dana Hoppe; Peter Stannek; Carmen Walter; Andrei Glinka; Christof Niehrs Journal: Nature Date: 2002-05-26 Impact factor: 49.962
Authors: Ulrike I Mödder; Kelley A Hoey; Shreyasee Amin; Louise K McCready; Sara J Achenbach; B Lawrence Riggs; L Joseph Melton; Sundeep Khosla Journal: J Bone Miner Res Date: 2011-02 Impact factor: 6.741
Authors: Pouneh K Fazeli; Irene S Wang; Karen K Miller; David B Herzog; Madhusmita Misra; Hang Lee; Joel S Finkelstein; Mary L Bouxsein; Anne Klibanski Journal: J Clin Endocrinol Metab Date: 2014-01-23 Impact factor: 5.958
Authors: Fatma Gossiel; Jessica R Scott; Margaret A Paggiosi; Kim E Naylor; Eugene V McCloskey; Nicola F A Peel; Jennifer S Walsh; Richard Eastell Journal: J Clin Endocrinol Metab Date: 2018-04-01 Impact factor: 5.958
Authors: Marcella D Walker; Natalie E Cusano; James Sliney; Megan Romano; Chiyuan Zhang; Donald J McMahon; John P Bilezikian Journal: Endocrine Date: 2012-10-26 Impact factor: 3.633
Authors: Kristine M Erlandson; MaryAnn O'Riordan; Corrilynn O Hileman; Eric Rapaport; Danielle Labbato; Thomas B Campbell; Grace A McComsey Journal: AIDS Res Hum Retroviruses Date: 2015-05-27 Impact factor: 2.205
Authors: Harjit Pal Bhattoa; John Wamwaki; Edit Kalina; Roza Foldesi; Adam Balogh; Peter Antal-Szalmas Journal: J Bone Miner Metab Date: 2013-03-24 Impact factor: 2.626